Naproxen/esomeprazole fixed-dose combination: For the treatment of arthritic symptoms and to reduce the risk of gastric ulcers

Drugs and Aging

Volumn 28, Issue 3, 2011, Pages 237-248

  Dhillon, Sohita ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

Adis Drug Profiles; Ankylosing spondylitis, treatment; Esomeprazole naproxen, pharmacodynamics; Esomeprazole naproxen, pharmacokinetics; Esomeprazole naproxen, therapeutic use; NSAID induced ulcer, prevention; Osteoarthritis, treatment; Research and development; Rheumatoid arthritis, treatment

Indexed keywords

CELECOXIB; ESOMEPRAZOLE; ESOMEPRAZOLE PLUS NAPROXEN; METHOTREXATE; NAPROXEN; OMEPRAZOLE; PLACEBO;

ABDOMINAL DISTENSION; ANALGESIC ACTIVITY; ANKYLOSING SPONDYLITIS; ANTIINFLAMMATORY ACTIVITY; ANTIPYRETIC ACTIVITY; ARTHRITIS; BIOEQUIVALENCE; DIARRHEA; DOSE RESPONSE; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DUODENITIS; DUODENUM ULCER; DYSPEPSIA; EROSIVE DUODENITIS; EROSIVE GASTRITIS; ESOPHAGITIS; GASTRITIS; HIATUS HERNIA; HUMAN; KNEE OSTEOARTHRITIS; MAXIMUM PLASMA CONCENTRATION; NAUSEA; PRIORITY JOURNAL; REFLUX ESOPHAGITIS; REVIEW; RHEUMATOID ARTHRITIS; STOMACH ULCER; TREATMENT OUTCOME; UPPER ABDOMINAL PAIN; UPPER RESPIRATORY TRACT INFECTION;

ANIMALS; ARTHRITIS; DRUG COMBINATIONS; DRUG DOSAGE CALCULATIONS; HUMANS; NAPROXEN; OMEPRAZOLE; STOMACH ULCER;

EID: 79951875924     PISSN: 1170229X     EISSN: 11791969     Source Type: Journal    
DOI: 10.2165/11207150-000000000-00000     Document Type: Review

References (25)

1. Peura DA, Goldkind L. Balancing the gastrointestinal benefits and risks of nonselective NSAIDs. Arthritis Res Ther 2005; 7 Suppl. 4: S7-13
2. Naesdal J, Brown K. NSAID-associated adverse effects and acid control aids to prevent them: a review of current treatment options. Drug Saf 2006; 29 (2): 119-32 (Pubitemid 43213886)
3. Lanza FL, Chan FK, Quigley EM. Guidelines for prevention of NSAID-related ulcer complications. Am J Gastroenterol 2009 Mar; 104 (3): 728-38
4. Blandizzi C, Tuccori M, Colucci R, et al. Clinical efficacy of esomeprazole in the prevention and healing of gastrointestinal toxicity associated with NSAIDs in elderly patients. Drugs Aging 2008; 25 (3): 197-208 (Pubitemid 351363752)
5. Musumba C, Pritchard DM, Pirmohamed M. Review article: cellular and molecular mechanisms of NSAID-induced peptic ulcers. Aliment Pharmacol Ther 2009 Sep 15; 30 (6): 517-31
6. Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med 1999 Jun 17; 340 (24): 1888-99 (Pubitemid 29272670)
7. Chan FK, Abraham NS, Scheiman JM, et al. Management of patients on nonsteroidal anti-inflammatory drugs: a clinical practice recommendation from the First International Working Party on Gastrointestinal and Cardiovascular Effects of Nonsteroidal Anti-inflammatory Drugs and Anti-platelet Agents. Am J Gastroenterol 2008 Nov; 103 (11): 2908-18
8. Scheiman JM, Fendrick AM. Summing the risk of NSAID therapy. Lancet 2007 May 12; 369 (9573): 1580-1 (Pubitemid 46710106)
9. Zhang W, Doherty M, Arden N, et al. EULAR evidence based recommendations for the management of hip osteoarthritis: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2005 May; 64 (5): 669-81 (Pubitemid 40559291)
10. Zhang W, Moskowitz RW, Nuki G, et al. OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis Cartilage 2008 Feb; 16 (2): 137-62 (Pubitemid 351222155)
11. Laine L, Connors L, Griffin MR, et al. Prescription rates of protective co-therapy for NSAID users at high GI risk and results of attempts to improve adherence to guidelines. Aliment Pharmacol Ther 2009 Oct; 30 (7): 767-74
12. Sturkenboom MC, Burke TA, Tangelder MJ, et al. Adherence to proton pump inhibitors or H2-receptor antagonists during the use of non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther 2003 Dec; 18 (11-12): 1137-47 (Pubitemid 38021600)
13. Goldstein JL, Hochberg MC, Fort JG, et al. Clinical trial: the incidence of NSAID-associated endoscopic gastric ulcers in patients treated with PN 400 (naproxen plus esomeprazole magnesium) vs. enteric-coated naproxen alone. Aliment Pharmacol Ther 2010 Aug; 32 (3): 401-13
14. Miner Jr P, Plachetka J, Orlemans E, et al. Clinical trial: evaluation of gastric acid suppression with three doses of immediate-release esomeprazole in the fixed-dose combination of PN 400 (naproxen/esomeprazole magnesium) compared with naproxen 500 mg and enteric-coated esomeprazole 20 mg: a randomized, open-label, phase I study in healthy volunteers. Aliment Pharmacol Ther 2010; 32 (3): 414-24
15. Brogden RN, Pinder RM, Sawyer PR, et al. Naproxen: a review of its pharmacological properties and therapeutic efficacy and use. Drugs 1975; 9 (5): 326-63
16. Todd PA, Clissold SP. Naproxen: a reappraisal of its pharmacology, and therapeutic use in rheumatic diseases and pain states. Drugs 1990 Jul; 40 (1): 91-137
17. McKeage K, Blick SKA, Croxtall JD, et al. Esomeprazole: a review of its use in the management of gastric acid-related diseases in adults. Drugs 2008; 68 (11): 1571-607 (Pubitemid 352001193)
18. AstraZeneca LP. Vimovo™ (naproxen and esomeprazole magnesium) delayed release tablets: US prescribing information [online]. Available from URL: http://www.accessdata.fda.gov/drugsatfda-docs/label/2010/022511lbl.pdf [Accessed 2010 Oct 29]
19. AstraZeneca UK Limited. Vimovo (naproxen/esomeprazole magnesium) 500 mg/20 mg modified-release tablets [online]. Available from URL: http://www.medicines.org.uk/EMC/medicine/23883/SPC/VIMOVO+500+mg+20+mg+modified- release+tablets/ [Accessed 2010 Nov 19]
20. Genta RM, Rindi G, Fiocca R, et al. Effects of 6-12 months of esomeprazole treatment on the gastric mucosa. Am J Gastroenterol 2003 Jun; 98 (6): 1257-65 (Pubitemid 36741519)
21. Fiocca R, Mastracci S, Attwood C, et al. Exocrine and endocrine gastric mucosal changes over 5 years in GERD patients undermedical or surgical antireflux therapy: final results from the LOTUS trial [abstract no. OP401]. 18th United European Gastroenterology Week; 2010 Oct 23-27; Barcelona
22. Bourre-Tessier J, Haraoui B. Methotrexate drug interactions in the treatment of rheumatoid arthritis: a systematic review. J Rheumatol 2010 Jul; 37 (7): 1416-21
23. Hassan-Alin M, Naesdal J, Nilsson-Pieschl C, et al. Lack of pharmacokinetic interaction between esomeprazole and the nonsteroidal anti-inflammatory drugs naproxen and rofecoxib in healthy subjects. Clin Drug Invest 2005; 25 (11): 731-40 (Pubitemid 41577413)
24. Hochberg MC, Cryer B, Fort JG, et al. A fixed-dose combination of naproxen and esomeprazole magnesium (Vimovo) has comparable efficacy and tolerability to celecoxib in patients with osteoarthritis (OA) of the knee: results from two randomized, controlled trials [abstract no. 937]. Arthritis Rheum 2010; 62 (10 Suppl.): S388. Plus poster presented at the 74th Annual Scientific Meeting of the American College of Rheumatology; 2010 Nov 7-11; Atlanta (GA)
25. Rabeneck L, Wristers K, Goldstein JL, et al. Reliability, validity, and responsiveness of severity of dyspepsia assessment (SODA) in a randomized clinical trial of a COX-2-specific inhibitor and traditional NSAID therapy. Am J Gastroenterol 2002 Jan; 97 (1): 32-9 (Pubitemid 34059761)